The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Results for Pembrolizumab Plus Standard Neoadjuvant Therapy for High-Risk Breast Cancer

Rita Nanda, MD
Published Online:9:00 PM, Thu July 6, 2017

Rita Nanda, MD, assistant professor of Medicine, assistant director, Breast Medical Oncology, discusses results from I-SPY 2, which explored pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer. 
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.